A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study

Basit Öğe Kaydı
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKiki, Ilhami
dc.contributor.authorKaya, Ali Hakan
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorAlacacioglu, Inci
dc.date.accessioned2024-04-24T16:18:31Z
dc.date.available2024-04-24T16:18:31Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractThrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic plasma exchange (TPE) due to a presumptive diagnosis of TMA, who had serum ADAMTSI3 activity/antiADAMTS13 antibody analysis at the time of hospital admission. The median age of the study cohort was 36 (14-84). 67 (43.5%), 32 (20.8%), 27 (17.5%) and 28 (18.2%) patients were diagnosed as thrombotic thrombocytopenic purpura (TTP), infection/complement-associated hemolytic uremic syndrome (IA/CAHUS), secondary TMA and TMA-not otherwise specified (TMA-NOS), respectively. Patients received a median of 18 (1-75) plasma volume exchanges for 14 (153) days. 81 (52.6%) patients received concomitant steroid therapy with TPE. Treatment responses could be evaluated in 137 patients. 90 patients (65.7%) achieved clinical remission following TPE, while 47 (34.3%) patients had non-responsive disease. 25 (18.2%) non-responsive patients died during follow-up. Our study present real-life data on the distribution and follow-up of patients with TMAs who were referred to therapeutic apheresis centers for the application of TPE. (C) 2018 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2018.02.012
dc.identifier.endpage30en_US
dc.identifier.issn1473-0502
dc.identifier.issue1en_US
dc.identifier.pmid29503132
dc.identifier.scopus2-s2.0-85042560693
dc.identifier.scopusqualityQ3
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2018.02.012
dc.identifier.urihttps://hdl.handle.net/11468/16143
dc.identifier.volume57en_US
dc.identifier.wosWOS:000436056500008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectThrombotic Microangiopathyen_US
dc.subjectThrombotic Thrombocytopenic Purpuraen_US
dc.subjectHemolytic-Uremic Syndromeen_US
dc.subjectTtpen_US
dc.subjectHusen_US
dc.titleA multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 studyen_US
dc.titleA multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu